Gut delivery of budesonide, a locally active corticosteroid, from plain and controlled-release capsules

被引:34
作者
Edsbäcker, S
Larsson, P
Wollmer, P
机构
[1] AstraZeneca Pharmaceut LP, Expt Med, Wayne, PA 19087 USA
[2] AstraZeneca R&D, Clin Sci, Lund, Sweden
[3] Malmo Univ Hosp, Dept Clin Physiol, Malmo, Sweden
关键词
budesonide; formulation; pharmacokinetics; absorption; Crohn's disease;
D O I
10.1097/00042737-200212000-00012
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective To compare the pharmacokinetics and site of uptake of budesonide from a control led-release formulation and a deuterium-labelled standard formulation given before and after a meal. Methods Six healthy volunteers were randomized into an open, crossover study. They received 4.5 mg controlled-release budesonide (mixed with In-111 pellets to trace gastrointestinal transit) and 4.8 mg H-2(8)-budesonide simultaneously at each of two visits: one visit before a standardized breakfast and the other after breakfast. Plasma concentrations of budesonide were followed over 24 h. The transit of the In-111 pellets through the gastrointestinal tract was followed for 36 h. Data on the site of absorption were calculated from transit times and absorption curves. Results The time to peak plasma concentration was significantly increased with controlled-release budesonide when compared with the deuterium-labelled standard formulation (before breakfast, 4.5 h vs 1.8 h; after breakfast, 5.2 h vs 2.9 h). When given after breakfast, the controlled-release formulation was associated with a mean residence time 1.6 h longer than that seen with the standard formulation. However, the areas under the plasma concentration curves were similar with the two formulations, regardless of when the treatments were given (before breakfast, 18.0 +/- 3.8 nmol/l vs 18.0 +/- 6.0 nmol/l; after breakfast, 16.9 +/- 7.0 nmol/l vs 18.5 +/- 9.0 nmol/l). Over 60% of the total budesonide absorbed from control led-release capsules was delivered and absorbed in the ileum and colon. The corresponding proportion for the standard formulation was approximately 33%. Conclusions Controlled-release budesonide effectively delivers most of the budesonide dose to the ileum and colon, the regions that are most often affected by inflammatory bowel disease. In addition, the time of food intake has little effect on the site of absorption or the bioavailability of the controlled-release formulation. Delivery to the colon and ileum was independent of whether the drug was given before or after breakfast.
引用
收藏
页码:1357 / 1362
页数:6
相关论文
共 14 条
[1]  
Brattsand R., 1990, Can J Gastroenterol, V4, P407
[2]   BUDESONIDE - AN UPDATED REVIEW OF ITS PHARMACOLOGICAL PROPERTIES, AND THERAPEUTIC EFFICACY IN ASTHMA AND RHINITIS [J].
BROGDEN, RN ;
MCTAVISH, D .
DRUGS, 1992, 44 (03) :375-407
[3]   Oral budesonide is as effective as oral prednisolone in active Crohn's disease [J].
Campieri, M ;
Ferguson, A ;
Doe, W ;
Persson, T ;
Nilsson, LG ;
Malchow, H ;
Prantera, C ;
Mani, V ;
OMorain, C ;
Selby, W ;
Pallone, F ;
diPietralata, MM ;
Sjodahl, R ;
Florin, T ;
Smith, P ;
Bianchi, P ;
Lofberg, R ;
Rutgeerts, P ;
Smallwood, R ;
Lamers, HW ;
TasmanJones, C ;
Hunter, JO ;
Hodgson, H ;
Danielsson, A ;
Lee, FI ;
Piacitelli, G ;
Giovanni, S ;
Ellis, A ;
Weir, DG .
GUT, 1997, 41 (02) :209-214
[4]   VARIATION IN GASTROINTESTINAL TRANSIT OF PHARMACEUTICAL DOSAGE FORMS IN HEALTHY-SUBJECTS [J].
COUPE, AJ ;
DAVIS, SS ;
WILDING, IR .
PHARMACEUTICAL RESEARCH, 1991, 8 (03) :360-364
[5]  
Edsbäcker S, 2000, DRUGS TODAY, V36, P9
[6]   ORAL BUDESONIDE FOR ACTIVE CROHNS-DISEASE [J].
GREENBERG, GR ;
FEAGAN, BG ;
MARTIN, F ;
SUTHERLAND, LR ;
THOMSON, ABR ;
WILLIAMS, CR ;
NILSSON, LG ;
PERSSON, T ;
BAIN, V ;
CHERRY, R ;
FEDORAK, R ;
LALOR, E ;
SHERBANIUK, R ;
YACYSHYN, B ;
KIERDEKIS, P ;
BAILEY, R ;
MEYER, D ;
FREEMAN, H ;
DAWS, P ;
HOLLAND, S ;
BUYTENDORP, M ;
WHITTAKER, S ;
CHANG, A ;
SUTHERLAND, L ;
HERSHFIELD, N ;
MACCANNELL, K ;
MEDDING, J ;
PRICE, L ;
SHAFFER, E ;
RACICOT, N ;
BASS, S ;
BRIDGES, R ;
BLUSTEIN, P ;
LAY, T ;
VANROSENDAAL, G ;
WATSON, M ;
WILLIAMS, CN ;
VANZANTEN, V ;
LEDDIN, D ;
FALKENHAM, J ;
TANTON, R ;
HUMAN, P ;
TURNBALL, G ;
SCHEP, G ;
WOOLNOUGH, J ;
DALLAIRE, C ;
ROSSEAU, B ;
BERNARD, F ;
DUBE, R ;
PARE, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (13) :836-841
[7]   RISK-BENEFIT ASSESSMENT OF DRUGS USED IN THE TREATMENT OF INFLAMMATORY BOWEL-DISEASE [J].
HANAUER, SB ;
STATHOPOULOS, G .
DRUG SAFETY, 1991, 6 (03) :192-219
[8]   DETERMINATION OF (22R,S)BUDESONIDE IN HUMAN PLASMA BY AUTOMATED LIQUID-CHROMATOGRAPHY THERMOSPRAY MASS-SPECTROMETRY [J].
LINDBERG, C ;
BLOMQVIST, A ;
PAULSON, J .
BIOLOGICAL MASS SPECTROMETRY, 1992, 21 (11) :525-533
[9]   Effect of food on the pharmacokinetics of budesonide controlled ileal release capsules in patients with active Crohn's disease [J].
Lundin, P ;
Naber, T ;
Nilsson, M ;
Edsbäcker, S .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (01) :45-51
[10]  
MILLER L R, 1989, Gastroenterology, V96, pA344